Fortrea 與 Omico 攜手合作，推動生物標記主導的腫瘤藥物開發

Fortrea, a leading Contract Research Organization (CRO), has partnered with Omico, Australia's precision oncology screening platform, to accelerate biomarker-driven cancer clinical trials in Australia. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve trial planning, site selection, and patient recruitment, leveraging Omico's database of over 23,000 consented patients and referrals from 1,600+ clinicians across Australia.